Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SHSE:603233'
s PEG Ratio Range Over the Past 10 Years
Min: 1.09 Med: 1.67 Max: 14.98
Current: 1.16
During the past 13 years, DaShenLin Pharmaceutical Group Co's highest PEG Ratio was 14.98. The lowest was 1.09. And the median was 1.67.
SHSE:603233's PEG Ratio is ranked better than 60.27% of 224
companies
in the Healthcare Providers & Services industry
Industry Median: 1.42
vs SHSE:603233: 1.16
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
DaShenLin Pharmaceutical Group Co (SHSE:603233) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
DaShenLin Pharmaceutical Group Co PEG Ratio Related Terms
DaShenLin Pharmaceutical Group Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co PEG Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co PEG Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a PEG Ratio of 1.16 as of Jul. 20, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. This is 31% below median its historical median of 1.67. Over the past decade, DaShenLin Pharmaceutical Group Co's PEG Ratio has ranged from 1.09 to 14.98. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #89 out of 224 companies in the Healthcare Providers & Services industry, placing it in the top 39.7%.
Is DaShenLin Pharmaceutical Group Co's PEG Ratio too high?
DaShenLin Pharmaceutical Group Co's current PEG Ratio of 1.16 is 31% below median its 10-year median of 1.67. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 14.98. The Healthcare Providers & Services industry median PEG Ratio is 1.42. DaShenLin Pharmaceutical Group Co's value of 1.16 is 18.3% below this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #89 out of 224 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's PEG Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #89 out of 224 companies for PEG Ratio. This puts DaShenLin Pharmaceutical Group Co in the upper half of its industry. The industry median PEG Ratio is 1.42. DaShenLin Pharmaceutical Group Co's value of 1.16 is 18.3% below this benchmark. Historically, DaShenLin Pharmaceutical Group Co's own PEG Ratio has ranged from 1.09 to 14.98 over the past decade. While the company's 10-year median is 1.67 vs. the industry median of 1.42, DaShenLin Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Healthcare Providers & Services company?
The median PEG Ratio among Healthcare Providers & Services companies is 1.42, based on 224 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current PEG Ratio of 1.16 is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median PEG Ratio is 1.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current PEG Ratio is 1.16, which is 31% below median its own 10-year median of 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.83, compared to a current price of ¥18.82 — trading 0.1% below its estimated fair value. The current PEG Ratio is 1.16, which is 31% below median its 10-year median of 1.67 and 18.3% below the Healthcare Providers & Services industry median of 1.42. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current PEG Ratio is 1.16 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥18.82 is trading 0.1% below its estimated GF Value™ of ¥18.83.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603233:
PEG Ratio: 1.16 (31% below median its 10-year median of 1.67)
GF Value™: ¥18.83 vs. price of ¥18.82 (0.1% below fair value)
Industry Position: 18.3% below the Healthcare Providers & Services median (#89 of 224)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Business Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
94GF Score
Get the complete analysis for SHSE:603233
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
